Boci Pharmaceuticals: Revenue in 2025 was 916 million yuan, a year-on-year decrease in net profit of 23.86%.

Foci Pharmaceuticals announced that in 2025, the company's revenue was 916 million yuan, a year-on-year decrease of 6.60%; net profit was 46.955 million yuan, a year-on-year decrease of 23.86%. The total assets at the end of the year were 2.547 billion yuan, an increase of 3.15% from the beginning of the year; the total liabilities were 692 million yuan, an increase of 5.69% from the beginning of the year; and the shareholders' equity was 1.855 billion yuan, an increase of 2.23% from the beginning of the year. The net cash flow from operating activities was 184 million yuan, a year-on-year increase of 371.85%. In terms of profitability, the sales gross profit margin increased by 3.50%, while the sales net profit margin and return on equity decreased. Overall, the solvency was stable and the operational capability tended to be stable.